Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The company is in the development stage with no commercial revenue to date. Its lead product, NB1, is currently undergoing a pilot clinical study.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Three Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,649,703) | $(783,733) |
| Operating Expenses | $1,713,202 | $809,665 |
| Research & Development (R&D) | $596,067 | $350,442 |
| General & Administrative (G&A) | $1,117,135 | $459,223 |
| Cash and Cash Equivalents (End of Period) | $2,332,068 | $2,332,068 |
| Net Cash Used in Operating Activities | $(2,199,276) | N/A |
| Net Cash Provided by Financing Activities | $1,504,775 | N/A |
| Accumulated Deficit | $(82,558,661) | $(82,558,661) |
| Warrant Liability | $7,655 | $7,655 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 72.3% for the six months ended June 30, 2024, compared to the same period in 2023. R&D expenses dropped 87.8% (from $4.9M to $0.6M) and G&A expenses dropped 14.2% (from $1.3M to $1.1M). Management attributes the R&D decline to significant one-time production costs for the NELL-1 protein incurred in 2023 for the initial clinical study.
- Net Loss Improvement: Net loss decreased by 69.9% year-over-year for the six-month period, driven primarily by reduced operating expenses and a significant decrease in the change in fair value of warrant liability (from a $707k expense in 2023 to a $48k expense in 2024).
- Capital Raise: In March 2024, the company completed a public offering raising approximately $1.5 million net of costs. This included the sale of common stock, warrants, and pre-funded warrants.
- Legal Settlement: The company paid an accrued legal settlement of $414,989 during the six months ended June 30, 2024, which was recorded as a liability in the prior year-end balance sheet.
Outlook, Risks, and Subsequent Events
- Going Concern: The company has incurred accumulated losses of approximately $82.6 million since inception. Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern. Operating expenditures for the next 12 months are estimated at $5.1 million.
- Subsequent Financing: On August 2, 2024, the company completed a warrant inducement transaction generating net proceeds of approximately $1.7 million. Management anticipates that available cash, inclusive of these proceeds, will cover operational needs into the first quarter of 2025.
- Clinical Progress: The first two patients were treated in the multicenter, prospective, randomized pilot clinical study of the NB1 bone graft device in June 2024. This triggered a $100,000 milestone payment to the UCLA Technology Development Group (UCLA TDG).
- Future Capital Needs: The company estimates it requires approximately $5 million to complete first-in-man studies and an additional $24 million in scientific expenses to achieve FDA approval for a spine interbody fusion indication.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, regulatory delays, and dependence on third-party manufacturers. The company is also subject to significant royalty and milestone obligations to UCLA TDG upon commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.7 million raised in August 2024 combined with existing cash to meet the estimated $5.1 million operating burn rate for the next 12 months.
- Dilution: Review the terms of the August 2024 warrant inducement and the March 2024 offering, noting the significant number of warrants outstanding (1,025,970 as of June 30, 2024) and potential future dilution.
- Clinical Milestones: Monitor the progress of the NB1 pilot clinical study and the associated $100,000 milestone payment to UCLA TDG already triggered.
- License Obligations: Assess the financial impact of the UCLA TDG license agreement, including the $8 million "Diligence Fee" payable upon the sale of licensed products and annual maintenance fees.
- Going Concern Status: Confirm if the company can secure additional financing before the first quarter of 2025 to avoid scaling back or discontinuing operations.